Dashboard
Manage Tickers

BPTH BIO-PATH HOLDINGS, INC.

Nasdaq biopathholdings.com


$ 0.00 (-1.3 %)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 602.96 $ 5.33 (0.89 %)
DIA $ 461.67 $ 2.33 (0.51 %)
SPY $ 663.26 $ 3.78 (0.57 %)
TLT $ 91.15 $ -0.08 (-0.09 %)
GLD $ 389.20 $ -7.96 (-2 %)
$ 0.0757
-- x --
-- x --
-- - --
$ 0.05 - $ 0.23
49,094
na
628,907
$ -0.52
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-07-2024 12-31-2023 10-K
8 08-14-2023 06-30-2023 10-Q
9 05-11-2023 03-31-2023 10-Q
10 03-30-2023 12-31-2022 10-K
11 11-14-2022 09-30-2022 10-Q
12 08-15-2022 06-30-2022 10-Q
13 05-16-2022 03-31-2022 10-Q
14 03-10-2022 12-31-2021 10-K
15 11-10-2021 09-30-2021 10-Q
16 08-12-2021 06-30-2021 10-Q
17 05-13-2021 03-31-2021 10-Q
18 03-09-2021 12-31-2020 10-K
19 11-12-2020 09-30-2020 10-Q
20 08-13-2020 06-30-2020 10-Q
21 05-14-2020 03-31-2020 10-Q
22 03-05-2020 12-31-2019 10-K
23 11-14-2019 09-30-2019 10-Q
24 08-14-2019 06-30-2019 10-Q
25 05-15-2019 03-31-2019 10-Q
26 03-19-2019 12-31-2018 10-K
27 11-14-2018 09-30-2018 10-Q
28 08-14-2018 06-30-2018 10-Q
29 05-15-2018 03-31-2018 10-Q
30 04-02-2018 12-31-2017 10-K
31 11-09-2017 09-30-2017 10-Q
32 08-09-2017 06-30-2017 10-Q
33 05-10-2017 03-31-2017 10-Q
34 03-15-2017 12-31-2016 10-K
35 11-09-2016 09-30-2016 10-Q
36 08-09-2016 06-30-2016 10-Q
37 05-10-2016 03-31-2016 10-Q
38 03-15-2016 12-31-2015 10-K
39 11-09-2015 09-30-2015 10-Q
40 08-10-2015 06-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

bio-path-holdings-q2-eps-055-misses-040-estimate
Bio-Path Holdings Q2 EPS $(0.55) Misses $(...
08/14/2025 21:42:48

Bio-Path Holdings (OTC:BPTH) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0....

bio-path-holdings-highlights-pipeline-progress-and-market-strategy-for-dnabilize-platform
Bio-Path Holdings Highlights Pipeline Prog...
06/03/2025 11:13:37

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and an...

bio-path-holdings-says-it-has-secured-third-pre-clinical-milestone-confirming-potential-of-bp1001-a-as-treatment-for-obesity-in-type-2-diabetes-patients
Bio-Path Holdings Says It Has Secured Thir...
05/01/2025 11:41:40

us-stocks-mixed-ny-state-business-activity-rises-in-february
US Stocks Mixed; NY State Business Activit...
02/18/2025 14:45:14

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
02/18/2025 12:05:41

bio-path-holdings-receives-patent-no-17339366-titled-p-ethoxy-nucleic-acids-for-stat3-inhibition-from-united-states-patent-and-trademark-office
Bio-Path Holdings Receives Patent No. 17/3...
02/13/2025 21:05:06

bio-path-announces-tumor-reduction-and-stable-disease-in-phase-11b-bp1001-a-trial-at-higher-dose-reports-patient-progress-in-phase-2-aml-study-with-prexigebersen
Bio-Path Announces Tumor Reduction And Sta...
02/13/2025 13:16:55

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction an...

bio-path-holdings-provides-update-from-phase-11b-clinical-trial-of-bp1002-for-treatment-of-refractoryrelapsed-acute-myeloid-leukemia-meaningful-patient-response-seen-trial-advances-to-90-mg-dose-cohort
Bio-Path Holdings Provides Update From Pha...
02/12/2025 21:25:29

Study Progresses to Fourth Higher 90 mg/m2 Dose CohortCompelling Patient Response Highlighted by Stable Disease and Significant...

bio-path-provides-a-clinical-development-and-operational-update-for-2025
Bio-path Provides A Clinical Development A...
01/10/2025 12:21:50

Clinical Program OverviewBio-Path's clinical development program consists of one Phase 2 clinical trial, two Phase 1 or 1/1...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
12/19/2024 21:06:40

nasdaq-jumps-100-points-us-initial-jobless-claims-decline
Nasdaq Jumps 100 Points, US Initial Jobles...
12/19/2024 19:25:09

bio-path-holdings-shares-were-on-the-rise-whats-going-on
Bio-Path Holdings Shares Were On The Rise:...
12/19/2024 17:27:16

Bio-Path Holdings, Inc. (NASDAQ: BPTH) shares are surging Thursday following the company's announcement of encouraging prec...

gold-falls-sharply-lamb-weston-shares-plunge
Gold Falls Sharply, Lamb Weston Shares Plunge
12/19/2024 17:24:52

bio-path-shares-halted-on-circuit-breaker-stock-now-up-2782
Bio-Path Shares Halted On Circuit Breaker,...
12/19/2024 15:38:26

bio-path-holdings-shares-resume
Bio-Path Holdings Shares Resume
12/19/2024 15:36:33

us-stocks-higher-micron-reports-downbeat-sales
US Stocks Higher, Micron Reports Downbeat ...
12/19/2024 15:30:09

bio-path-holdings-shares-resume-trade
Bio-Path Holdings Shares Resume Trade
12/19/2024 14:51:13

bio-path-holdings-shares-halted-on-circuit-breaker-to-the-downside-stock-now-up-341
Bio-Path Holdings Shares Halted On Circuit...
12/19/2024 14:42:20

bio-path-shares-halted-on-circuit-breaker
Bio-Path Shares Halted On Circuit Breaker
12/19/2024 14:34:59

bio-path-reported-that-results-from-preclinical-studies-of-bp1001-a-for-obesity-demonstrated-enhanced-insulin-sensitivity-confirming-bp1001-a-as-a-potential-treatment-for-obesity-and-related-metabolic-diseases-in-type-2-diabetes-patients
Bio-Path Reported That Results From Precli...
12/19/2024 12:10:56

BP1001-A downregulates growth factor receptor-bound protein 2 (Grb2) expression to increase insulin sensitivity and helps lower...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION